Popular
Practical Dermatology July 2026: Page-Turner Format
Practical DermatologyPractical Dermatology July 2026: Page-Turner Format
Face Value with Modern Aesthetics: Burnout’s Hidden Aging Effects
Modern AestheticsFace Value with Modern Aesthetics: Burnout’s Hidden Aging Effects
How to Get Young People to Wear Sunscreen
Practical DermatologyHow to Get Young People to Wear Sunscreen
Putting It All Together: A Practical IBD Treatment Selection Primer
MinuteCE®Putting It All Together: A Practical IBD Treatment Selection Primer
Programs
Navigating IBD Guidelines: What Clinicians Need to Know Now
MinuteCE®Navigating IBD Guidelines: What Clinicians Need to Know Now
Small Molecules in IBD: JAK Inhibitors and S1P Modulators
MinuteCE®Small Molecules in IBD: JAK Inhibitors and S1P Modulators
The Future of Biologic Treatment in IBD: What’s on the Horizon
MinuteCE®The Future of Biologic Treatment in IBD: What’s on the Horizon
Gut-Selective Therapy: Understanding Anti-Integrins in IBD
MinuteCE®Gut-Selective Therapy: Understanding Anti-Integrins in IBD
Face Value with Modern Aesthetics: Biology Behind Medication-Driven Weight Loss Changes
Modern AestheticsFace Value with Modern Aesthetics: Biology Behind Medication-Driven Weight Loss Changes
Clinical Practice
Beyond One-Size-Fits-All: Individualizing First-Line IBD Treatment
MinuteCE®Beyond One-Size-Fits-All: Individualizing First-Line IBD Treatment
Expert Answers to Your Pressing Questions on the CALIBRATE Trial in ADH1
EndocrinologyExpert Answers to Your Pressing Questions on the CALIBRATE Trial in ADH1
Finerenone Efficacy and Safety in Patients With CKD Regardless of Diabetes Status: Insights From the INFINITY Dataset
NephrologyFinerenone Efficacy and Safety in Patients With CKD Regardless of Diabetes Status: Insights From the INFINITY Dataset
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Oncology and HematologyTROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Oncology and HematologyDESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
MinuteCE®SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
Doctors Lounge
Optimizing Medical Affairs Approaches with CME Best Practices
MAPSChatsOptimizing Medical Affairs Approaches with CME Best Practices
Inside Medical Affairs: MSL Insights on AI, Strategy, and Impact
MAPSChatsInside Medical Affairs: MSL Insights on AI, Strategy, and Impact
Turning Insight into Action: The Expanding Role of Medical Affairs
MAPSChatsTurning Insight into Action: The Expanding Role of Medical Affairs
Navigating Vaccine Communication: A Medical Affairs Perspective
MAPSChatsNavigating Vaccine Communication: A Medical Affairs Perspective
Rehumanizing Healthcare with AI: Turning Data Into Meaningful Outcomes
MAPSChatsRehumanizing Healthcare with AI: Turning Data Into Meaningful Outcomes
“We have the opportunity to understand what happens when someone leaves the clinic,” says Dr. Rajiv Kumar of Apple and Stanford Medicine
The Convergence“We have the opportunity to understand what happens when someone leaves the clinic,” says Dr. Rajiv Kumar of Apple and Stanford Medicine
CME
Translating Advances into Practice: Lessons from Today’s IBD Landscape
MinuteCE®Translating Advances into Practice: Lessons from Today’s IBD Landscape
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
MinuteCE®Ongoing Trials in Oral Targeted Strategies in Breast Cancer
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
CME/CE Virtual EventPrecision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
July 08, 2026
06:00 PM - 07:30 PM ET
Case: Implementing ADT Intensification in mHSPC
MinuteCE®Case: Implementing ADT Intensification in mHSPC
ADT Intensification: The Evidence You Can’t Afford to Miss
MinuteCE®ADT Intensification: The Evidence You Can’t Afford to Miss
Sjögren’s Myth Busters: Can You Detect Fact from Fiction on Emerging Therapies?
CME/CESjögren’s Myth Busters: Can You Detect Fact from Fiction on Emerging Therapies?
Industry Feature
Redefining Durability in Wet AMD: Insights from the SOL‑1 Superiority Trial
Medical Industry FeatureRedefining Durability in Wet AMD: Insights from the SOL‑1 Superiority Trial
Depression from Case to Clinic: Rethinking Partial Response with a Different Approach
Medical Industry FeatureDepression from Case to Clinic: Rethinking Partial Response with a Different Approach
Treatment Decisions in mCSPC: A Review of Retrospective Real-World Evidence
Medical Industry FeatureTreatment Decisions in mCSPC: A Review of Retrospective Real-World Evidence
Expandable Cages Enhance Minimally Invasive Spinal Fusion
Medical Industry FeatureExpandable Cages Enhance Minimally Invasive Spinal Fusion
Debunking Five Misconceptions in Agitation in Alzheimer’s Dementia
Medical Industry FeatureDebunking Five Misconceptions in Agitation in Alzheimer’s Dementia
Engaging Patients and Caregivers About Digital Therapeutics
Medical Industry FeatureEngaging Patients and Caregivers About Digital Therapeutics
















































































































































